Clinical trials: Dialysis Patients
Chronic Kidney Disease
Dialysis Clinical Outcomes Revisited (DCOR) Trial
This is a randomized, open-label, parallel-design study to be conducted at 75 centers within the United States. The study will be described to hemodialysis patients.
- Trial name
- NCT00324571
- Testing
- Sevelamer hydrochloride, Calcium-based phosphate binder
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Cardiovascular Disease, Chronic Kidney Failure
Effect of HCO1100 on Cardiovascular Function
The purpose of this study is to determine whether high porous membranes are effective in the treatment of cardiovascular events in chronic dialysis patients.
- Trial name
- HicoCARD (NCT01363921)
- Testing
- HCO 1100
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Vantive Health LLC
Hyperkalemia
A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.
The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.
- Trial name
- DIALIZE (NCT03303521)
- Testing
- Sodium Zirconium Cyclosilicate (ZS)
- Where
- 53 sites in United States, Japan and 2 more
- Volunteers
- 196 people
- Sponsor
- AstraZeneca
Anemia
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
This single arm study will assess the efficacy and safety of subcutaneous Mircera for the correction and maintenance of hemoglobin levels in predialysis patients with renal anemia who are not currently treated with ESA.
- Trial name
- NCT00680563
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 22 sites in Argentina, Brazil and 8 more
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Dialysis; Complications, Vascular Access Complication
Access Cannulation Trial II
This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating…
- Trial name
- ACT II (NCT05490225)
- Testing
- VenaSure
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Voyager Biomedical
End Stage Renal Failure on Dialysis, End Stage Renal Disease on Dialysis
Human Factors Validation Testing for the Peripal System; a Manual Connection Assist Device for Peritoneal Dialysis Devices
It is estimated that there are currently over 3 million patients receiving dialysis treatment worldwide. With effective pre-dialysis counselling, a majority of patients choose the home-based therapy peritoneal dialysis (PD) but…
- Conditions
- End Stage Renal Failure on Dialysis, End Stage Renal Disease on Dialysis, Renal Failure, Peritoneal Dialysis
- Trial name
- NCT04292210
- Testing
- Perisafe
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Peripal AG
Anemia
A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
This single arm study will evaluate the maintenance of hemoglobin levels, safety and tolerability of once-monthly intravenous administration of Mircera in dialysis patients with chronic renal anemia.
- Trial name
- NCT00737464
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 17 sites in India
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin.
- Trial name
- NCT00077623
- Testing
- epoetin alfa or beta, methoxy polyethylene glycol-epoetin beta (Mircera)
- Where
- 90 sites in United States, Belgium and 19 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin.
- Trial name
- NCT00077610
- Testing
- Epoetin alfa or beta, RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks)
- Where
- 99 sites in United States, Canada and 6 more
- Volunteers
- 673 people
- Sponsor
- Hoffmann-La Roche
End Stage Renal Disease (ESRD)
Bayston Multicenter Antimicrobial PD Catheter Safety Study
The study was designed to establish the safety of the Bayston Antimicrobial PD catheter that is impregnated with a "cocktail" of three well known anti-microbials
- Trial name
- Bayston (NCT02274896)
- Testing
- PD Catheter group
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Sponsor
- Medical Components, Inc dba MedComp
Anemia
A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia
This single arm study will assess the efficacy, safety and tolerability of once monthly administration of subcutaneous Mircera for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia.
- Trial name
- NCT00882713
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 12 sites in Morocco
- Volunteers
- 202 people
- Sponsor
- Hoffmann-La Roche
Renal Failure Acute Chronic
Efficacy and Tolerability of the APD Treatment in PAED Patients
The Silencia PD (peritoneal dialysis) cycler offers a pediatric (PAED) mode with advanced features such as Time and Volume Optimization (TAVO), supporting precise and individualized treatment.
- Trial name
- SilenciaPAED (NCT07004907)
- Testing
- Treatment with the pedriatic mode of the APD cycler
- Volunteers
- 13 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Kidney Failure, Chronic, Renal Dialysis
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
The purpose of this this study is to investigate the clinical utility of renal denervation in the treatment of ESRD patients with refractory hypertension.
- Trial name
- NCT00753116
- Testing
- Renal Denervation with a catheter-based procedure
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medtronic Vascular
Anemia
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.
This 2 arm study will compare the efficacy of monthly Mircera and epoetin alfa in peritoneal dialysis patients who self-inject at home or receive in-centre injections.
- Trial name
- NCT00442416
- Testing
- Epoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 29 sites in United States
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
This study will assess the efficacy and safety of methoxy polyethylene glycol-epoetin beta (Mircera) in the maintenance of hemoglobin levels in patients who have previously received treatment with epoetin alfa or darbepoetin…
- Trial name
- NCT00454246
- Testing
- methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
- Where
- 78 sites in United States
- Volunteers
- 111 people
- Sponsor
- Hoffmann-La Roche
Secondary Hyperparathyroidism, Dialysis
Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
Prospective, non-randomized, multi-center study to assess the efficacy and safety of paricalcitol injection or oral administered over 6 months to patients with secondary hyperparathyroidism on dialysis.
- Trial name
- NCT00537979
- Testing
- Paricalcitol injection, Paricalcitol capsules
- Where
- 12 sites in Mexico
- Volunteers
- 147 people
- Sponsor
- Abbott
Chronic Kidney Disease
A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis…
- Trial name
- NCT02988973
- Testing
- roxadustat, DA
- Where
- 66 sites in Japan
- Volunteers
- 334 people
- Sponsor
- Astellas Pharma Inc
Needle Phobia, Phobic Disorders
Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias
An arteriovenous fistula or graft access (AVF/AVG) for dialysis is often considered a superior option for delivery of dialysis, but requires needles to be inserted.
- Trial name
- NCT01623583
- Testing
- Enhanced Needle Phobia Intervention, Standard Needle Phobia Intervention
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Davita Clinical Research
Anemia
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients
The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.
- Trial name
- NCT00255424
- Testing
- ferumoxytol or oral iron
- Where
- 19 sites in United States
- Volunteers
- 304 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Chronic Kidney Disease, End Stage Renal Disease
TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment.
- Trial name
- NCT02117427
- Testing
- MDGN201 TARGTEPO
- Where
- 5 sites in Israel
- Volunteers
- 11 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company